<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-122861" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Remdesivir</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Aleem</surname>
            <given-names>Abdul</given-names>
          </name>
          <aff>Lehigh Valley Health Network, Allentown, USA</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kothadia</surname>
            <given-names>Jiten P.</given-names>
          </name>
          <aff>University of Tennessee Health Science Center, James D. Eason Transplant Institute</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdul Aleem declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jiten Kothadia declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-122861.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Remdesivir is a broad-spectrum antiviral agent that has showcased its efficacy against a spectrum of viruses, including filoviruses (eg, Ebola, Marburg), coronaviruses (eg, SARS-CoV, MERS-CoV, SARS-CoV-2), paramyxoviruses (eg, parainfluenza type III, Nipah, Hendra, measles, mumps), and Pnemoviridae (eg, respiratory syncytial virus). In vitro studies have demonstrated its antiviral activity against SARS-CoV-2, prompting its consideration as an investigational drug early in the pandemic. Following randomized clinical trials affirming superior clinical efficacy compared to placebo, remdesivir was the first antiviral drug approved by the US Food and Drug Administration (FDA). This approval signifies its role in the clinical management of patients with severe suspected or laboratory-confirmed COVID-19. This activity meticulously explores remdesivir's pharmacology, dosing, indications, contraindications, and potential adverse events to enhance patient outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate candidates for remdesivir therapy based on clinical criteria, such as severe COVID-19 infection and specific patient characteristics.</p></list-item><list-item><p>Apply knowledge of the current clinical evidence and guidelines to determine the optimal timing and duration of remdesivir therapy for individual patients.</p></list-item><list-item><p>Assess treatment response and monitor patients for potential adverse effects, such as liver function abnormalities, renal impairment, and infusion-related reactions.</p></list-item><list-item><p>Develop collaboration with infectious disease specialists, pharmacists, and other healthcare professionals to ensure coordinated care, address any challenges, and optimize the use of remdesivir.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=122861&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=122861">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-122861.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Remdesivir is a broad-spectrum antiviral agent that has previously demonstrated antiviral activity against filoviruses (eg, Ebola viruses, Marburg virus), coronaviruses (eg, SARS-CoV, MERS-Co-V, SARS-CoV-2), paramyxoviruses (eg, parainfluenza type III virus, Nipah virus, Hendra virus, measles, and mumps virus), and <italic toggle="yes">Pnemoviridae</italic> (eg, respiratory syncytial virus).<xref ref-type="bibr" rid="article-122861.r1">[1]</xref><xref ref-type="bibr" rid="article-122861.r2">[2]</xref><xref ref-type="bibr" rid="article-122861.r3">[3]</xref>&#x000a0;Remdesivir was initially developed against the Ebola virus based on its antiviral properties demonstrated in vitro and in vivo in animal models. However, it failed to demonstrate efficacy in randomized clinical trials.<xref ref-type="bibr" rid="article-122861.r4">[4]</xref><xref ref-type="bibr" rid="article-122861.r5">[5]</xref>&#x000a0;</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Remdesivir exhibited antiviral activity against SARS-CoV-2 studies in vitro and was initially proposed as an investigational drug early during the COVID-19 pandemic. However, based on data from a multinational, double-blind, randomized placebo-controlled trial that evaluated the efficacy of remdesivir in hospitalized patients with mild, moderate, or severe COVID-19 demonstrated that remdesivir was superior to placebo in shortening the time to clinical recovery, remdesivir&#x000a0;became the first antiviral drug to receive approval&#x000a0;by the US Food and Drug Administration (FDA) for clinical use in adults and pediatric patients meeting the following criteria:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Patients 28 days and older and weighing 3kgs or more with a laboratory-confirmed positive SARS-CoV-2 test who are&#x000a0;hospitalized</p>
          </list-item>
          <list-item>
            <p>Patients with mild-to-moderate COVID-19 who are non-hospitalized but are at high risk for progression to severe COVID-19, including hospitalization or death.<xref ref-type="bibr" rid="article-122861.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>The National Institutes of Health (NIH) COVID-19 treatment guidelines panel currently recommends the use of either remdesivir alone in hospitalized patients who are at high risk of progressing to severe COVID-19&#x000a0;or dexamethasone plus remdesivir or dexamethasone alone if combination therapy (remdesivir and dexamethasone) is not available in patients who require supplemental oxygen but are not receiving HFNC or NIPPV or IMV or ECMO.</p>
          </list-item>
        </list>
        <p>
<bold>Pertinent Studies Against SARS-CoV-2 Variants and Ongoing Trials&#x000a0;and Information</bold>
</p>
        <p>The efficacy of remdesivir alone or in combination with other drugs has not been evaluated in the SARS-CoV-2 variants, and clinical trials are ongoing. However,&#x000a0;as with other antiviral drugs, there is always a concern&#x000a0;regarding acquiring resistance against mutant viruses.</p>
        <p>Remdesivir has demonstrated in vitro antiviral activity against the Omicron variant (B.1.1.529).<xref ref-type="bibr" rid="article-122861.r7">[7]</xref>&#x000a0;A recent study evaluating the effect of available antiviral drugs against COVID-19, including remdesivir, may also have therapeutic value against the Omicron subvariants BA.2.12.1, BA.4, and BA.5.<xref ref-type="bibr" rid="article-122861.r8">[8]</xref></p>
      </sec>
      <sec id="article-122861.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Remdesivir (GS-5734) is a phosphoramidite prodrug of a monophosphate nucleoside analog (GS-441524) and acts as a viral RNA-dependent RNA polymerase (RdRp) inhibitor, targeting the viral genome replication process.<xref ref-type="bibr" rid="article-122861.r9">[9]</xref><xref ref-type="bibr" rid="article-122861.r5">[5]</xref></p>
        <p>Theoretically, nucleoside analogs do not permeate through the cell wall easily. Upon their subsequent entry into the host cell, they require phosphorylation to produce nucleoside triphosphate (NTP), which resembles adenosine triphosphate (ATP) and can be used by the RdRp enzymes or complexes for genome replication.<xref ref-type="bibr" rid="article-122861.r10">[10]</xref><xref ref-type="bibr" rid="article-122861.r11">[11]</xref><xref ref-type="bibr" rid="article-122861.r12">[12]</xref></p>
        <p>Once remdesivir is metabolized by the host cells into its pharmacologically active analog adenosine triphosphate (GS-443902), it competes with ATP for integration by the RdRp complex into the nascent RNA strand and, upon subsequent incorporation of a few more nucleotides, results in termination of RNA synthesis limiting viral replication.<xref ref-type="bibr" rid="article-122861.r10">[10]</xref><xref ref-type="bibr" rid="article-122861.r5">[5]</xref></p>
        <p>Remdesivir demonstrated potent antiviral activity against SARS-CoV-2 in vitro in primary human airway epithelial cultures and human lung cells. Remdesivir also had a dose-dependent inhibitory effect on SARS-CoV-2 replication with a half-maximal effective concentration (EC50).<xref ref-type="bibr" rid="article-122861.r13">[13]</xref><xref ref-type="bibr" rid="article-122861.r14">[14]</xref><bold>&#x000a0;</bold></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>Data regarding the pharmacokinetics of remdesivir is limited. A randomized controlled study evaluating the pharmacokinetics of single-dose and multiple-dose remdesivir compared to placebo in healthy subjects reported that following single-dose IV administration of remdesivir over 2 hours, remdesivir and its metabolites exhibited a linear profile across the study doses that ranged from 3&#x000a0;to 225 mg with both solution and lyophilized formulations also displaying similar pharmacokinetic parameters.<xref ref-type="bibr" rid="article-122861.r15">[15]</xref><bold>&#x000a0;</bold></p>
        <p>Remdesivir is a substrate of organic anion transporting polypeptide OATP1B1, OATP1B3,<bold>&#x000a0;</bold>and P-glycoprotein (P-gp) transporters and many cytochrome P450 (CYP450) that include CYP2C8, CYP2D6, and CYP3A4 and is considered to be an inhibitor of CYP enzymes in vitro; however, there has been no evidence of CYP induction by remdesivir and its metabolites in vivo.&#x000a0;However, based on&#x000a0;the drug's route of administration and rapid elimination,&#x000a0;remdesivir's potential to cause clinically significant drug-drug interactions (DDIs) may be limited<bold>.</bold><xref ref-type="bibr" rid="article-122861.r16">[16]</xref><xref ref-type="bibr" rid="article-122861.r17">[17]</xref>&#x000a0;Nevertheless, further clinical studies are required to evaluate&#x000a0;the drug's interaction with the cytochrome P450 system, which would determine the potential drug-drug interactions with remdesivir.</p>
      </sec>
      <sec id="article-122861.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Adult Dosing</bold>
</p>
        <p>The current recommended dose of remdesivir for&#x000a0;adults and pediatric patients hospitalized with suspected or laboratory-confirmed COVID-19 infection is weight-based, and administration is via the IV route. Before initiating remdesivir, a baseline renal function panel, hepatic function panel, and PT/INR must be performed per FDA recommendations. If the patient's eGFR is &#x0003c;30 mL/min, clinicians should avoid using remdesivir; eGFR &#x0003e;30 mL/min requires no dosing adjustments. Hepatic dosing is undefined at present.</p>
        <p>
<bold>Adults and Pediatric Patients Weighing&#x000a0;&#x02265;40 kg</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Mild-to-moderate disease: 200 mg IV should be given as a loading dose on day 1, followed by a maintenance dose of 100 mg IV every 24 hours for&#x000a0;2 additional days. The drug should be started ASAP within&#x000a0;7 days of symptomatic onset.</p>
          </list-item>
          <list-item>
            <p>Severe disease:&#x000a0;200 mg IV as a loading dose on day 1, followed by a maintenance dose of 100 mg IV&#x000a0;every 24 hours for&#x000a0;4 additional days. The drug can be given with baricitinib per the FDA Emergency Use&#x000a0;Authorization.</p>
          </list-item>
        </list>
        <p>
<bold>Pediatric Dosing</bold>
</p>
        <p>
<bold>Patients &#x02265;28 days and weighing &#x02265;3 kgs to &#x0003c;40 kg</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Mild-to-moderate disease:&#x000a0;5 mg/kg/dose IV for a single dose, then 2.5 mg/kg/dose IV every 24 hours for&#x000a0;2 days. The drug should be started ASAP within&#x000a0;7 days of symptomatic onset.</p>
          </list-item>
          <list-item>
            <p>Severe disease not requiring mechanical ventilation or extracorporeal membrane oxygenation (ECMO):&#x000a0;5 mg/kg/dose IV for a single dose, then 2.5 mg/kg/dose IV every 24 hours for&#x000a0;4 days.</p>
          </list-item>
        </list>
        <p>Remdesivir has also received approval for use in a non-hospital setting with mild-to-moderate COVID-19 who are non-hospitalized but are at high risk for progression to severe COVID-19, including hospitalization or death, and the optimal treatment duration for COVID-19 is&#x000a0;3 days.</p>
        <p>However, treatment may be extended an additional 5 days for patients requiring invasive mechanical ventilation or ECMO support. However, for patients not requiring invasive mechanical ventilation or ECMO support, remdesivir can be administered for&#x000a0;5 days with a recommendation to extend treatment duration for&#x000a0;5 additional days if no clinical response is seen in the first&#x000a0;5 days, for a total treatment duration of 10 days.</p>
        <p>
<bold>Special Patient Populations</bold>
</p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>No human data regarding remdesivir during pregnancy or breastfeeding is available. The benefits outweigh the risks in pregnancy.</p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>No human data regarding remdesivir during pregnancy or breastfeeding is available.&#x000a0;Clinicians must assess the benefit-to-risk ratio for breastfeeding patients.</p>
      </sec>
      <sec id="article-122861.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Clinical data about the adverse effects of remdesivir is limited. A randomized, blinded, placebo-controlled, phase I study evaluating the tolerability and safety profile of single-dose and multiple-dose remdesivir compared to placebo in healthy subjects reported that remdesivir was well tolerated in both subjects study groups with no serious adverse effects or associated mortality.<xref ref-type="bibr" rid="article-122861.r15">[15]</xref>&#x000a0;</p>
        <p>Based on a review of available literature from randomized clinical trials, the following are the potential organ-based adverse effects reported with the use of remdesivir:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Cardiovascular</bold>: Hypotension, arrhythmias, and cardiac arrest&#x000a0;<xref ref-type="bibr" rid="article-122861.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Pulmonary: </bold>Dyspnea, acute respiratory failure, acute respiratory distress, pneumothorax, pulmonary embolism</p>
          </list-item>
          <list-item>
            <p><bold>Hematological: </bold>Anemia, lymphopenia, coagulopathy&#x000a0;<xref ref-type="bibr" rid="article-122861.r18">[18]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Endocrine</bold>: Hyperglycemia</p>
          </list-item>
          <list-item>
            <p><bold>Infectious</bold>: Pneumonia, septic shock</p>
          </list-item>
          <list-item>
            <p><bold>Gastrointestinal:</bold> Nausea is the most commonly reported side effect in patients receiving remdesivir. Other side effects, such as elevated lipase vomiting, diarrhea, constipation, poor appetite, gastroparesis, and lower GI bleeding, have also been reported&#x000a0;<xref ref-type="bibr" rid="article-122861.r19">[19]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Hepatic: </bold>Hepatic manifestations characterized by Grade 1&#x000a0;to 4 increase in serum transaminases (ALT and AST) are the other most common adverse effects in patients treated with remdesivir. Other abnormalities include hyperbilirubinemia.<xref ref-type="bibr" rid="article-122861.r20">[20]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Renal and Metabolic:</bold> Acute kidney injury or worsening of underlying chronic kidney disease, hypernatremia, hypokalemia&#x000a0;<xref ref-type="bibr" rid="article-122861.r21">[21]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Neurological</bold>: Headache, lightheadedness</p>
          </list-item>
          <list-item>
            <p><bold>Skin: </bold>Rash, contact dermatitis, pruritus&#x000a0;<xref ref-type="bibr" rid="article-122861.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Psychiatric</bold>: Delirium&#x000a0;<xref ref-type="bibr" rid="article-122861.r23">[23]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Other adverse effects: </bold>Pyrexia, insomnia, multi-organ dysfunction, DVT, and hypersensitivity/anaphylactic reactions related to the infusion&#x000a0;<xref ref-type="bibr" rid="article-122861.r24">[24]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-122861.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Based on the guidance from the documentation published by the European Medicines Agency (EMA, 2020) and U.S FDA issued EUA, remdesivir is contraindicated in the following clinical situations unless the potential benefit of the use of remdesivir outweighs the potential risks:</p>
        <list list-type="bullet">
          <list-item>
            <p>Patients with alanine aminotransferase (ALT) levels &#x0003e;5 times the upper limit of normal or severe hepatic dysfunction</p>
          </list-item>
          <list-item>
            <p>Adult and pediatric patients (&#x0003e;28 days old) with severe renal impairment described as eGFR &#x0003c; 30 mL/min</p>
          </list-item>
          <list-item>
            <p>Neonates (at least&#x000a0;7 days to&#x000a0;&#x02264; 28 days old) with serum creatinine &#x02265;1 mg/dL</p>
          </list-item>
          <list-item>
            <p>Hypersensitivity to the drug or any ingredient</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-122861.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Due to limited clinical experience with remdesivir, randomized clinical trials evaluating data evaluating possible drug-drug interactions are currently unavailable. Since remdesivir is metabolized by cytochrome P450 (CYP450), there is potential drug-drug interaction.</p>
        <p>Remdesivir is extensively metabolized in the liver by carboxylesterase 1 and primarily eliminated in urine as the nucleoside metabolite GS-441524 based on the results of human mass balance studies.<xref ref-type="bibr" rid="article-122861.r16">[16]</xref></p>
        <p>Published data evaluating the safety of remdesivir in pediatric patients (younger than 12) and pregnant or breastfeeding women&#x000a0;are limited. Compassionate use of remdesivir was well tolerated and demonstrated the highest rates of recovery and shortest median time to recovery in pregnant and postpartum women with severe COVID-19.<xref ref-type="bibr" rid="article-122861.r25">[25]</xref></p>
        <p>The pharmacokinetics of remdesivir have not been assessed in patients younger than 65. Nevertheless, given the limited data regarding the safety profile of remdesivir, clinicians should closely monitor for any acute changes in the clinical status of drug-drug reactions. Relevant laboratory panels should be taken before and after the initiation of remdesivir in adults and pediatric patients hospitalized with suspected or laboratory-confirmed COVID-19 infection.</p>
      </sec>
      <sec id="article-122861.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Currently, there is a lack of clinical trial data describing the toxicity associated with remdesivir. However, a&#x000a0;randomized, blinded, placebo-controlled, phase I study evaluating the pharmacokinetics, tolerability, and safety profile of single-dose and multiple-dose remdesivir compared to placebo in healthy subjects reported that remdesivir was well tolerated in both study groups with no toxic severe effects or associated mortality with its clinical use.</p>
      </sec>
      <sec id="article-122861.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Remdesivir was the first drug available approved by the US Food and Drug Administration (FDA) for clinical use in managing patients with severe suspected or laboratory-confirmed COVID-19 infection.</p>
        <p>Although remdesivir has been approved by the FDA, there is limited published data regarding its long-term adverse effects and interaction with other drugs. Hence, its clinical use in patients hospitalized with COVID-19 illness requires an interprofessional team that includes&#x000a0;clinicians&#x000a0;across specialties and pharmacists who should be aware of the mechanism of action, potential side effects, drug-drug interactions, and recommended dose of remdesivir.</p>
        <p>The patient should receive the fact sheet issued by the US FDA before receiving the drug. Close communication and shared decision-making need to occur between the ordering physician, the pharmacist, and the nursing staff.&#x000a0;This interprofessional&#x000a0;approach would lead to the early identification of potential adverse effects and drug-drug interactions associated with remdesivir and help patients achieve optimal outcomes.</p>
      </sec>
      <sec id="article-122861.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=122861&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=122861">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/122861/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=122861">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-122861.s11">
        <title>References</title>
        <ref id="article-122861.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Warren</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Jordan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lo</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Ray</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Mackman</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Soloveva</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Perron</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bannister</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hui</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Larson</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Strickley</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stuthman</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Van Tongeren</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Garza</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Donnelly</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Shurtleff</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Retterer</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Gharaibeh</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zamani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kenny</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Eaton</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Grimes</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Welch</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Gomba</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wilhelmsen</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Nichols</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Nuss</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Nagle</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Kugelman</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Palacios</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Doerffler</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Neville</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carra</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Clarke</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lew</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Chun</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wolfe</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Babusis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Stray</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Trancheva</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Barauskas</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Flint</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McMullan</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Fearns</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Swaminathan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mayers</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Spiropoulou</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Nichol</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Cihlar</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bavari</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys.</article-title>
            <source>Nature</source>
            <year>2016</year>
            <month>Mar</month>
            <day>17</day>
            <volume>531</volume>
            <issue>7594</issue>
            <fpage>381</fpage>
            <page-range>381-5</page-range>
            <pub-id pub-id-type="pmid">26934220</pub-id>
          </element-citation>
        </ref>
        <ref id="article-122861.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lo</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Jordan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Arvey</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sudhamsu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shrivastava-Ranjan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hotard</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Flint</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McMullan</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Clarke</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Mackman</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Hui</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Perron</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ray</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Cihlar</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nichol</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Spiropoulou</surname>
                <given-names>CF</given-names>
              </name>
            </person-group>
            <article-title>GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses.</article-title>
            <source>Sci Rep</source>
            <year>2017</year>
            <month>Mar</month>
            <day>06</day>
            <volume>7</volume>
            <fpage>43395</fpage>
            <pub-id pub-id-type="pmid">28262699</pub-id>
          </element-citation>
        </ref>
        <ref id="article-122861.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sheahan</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Sims</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Menachery</surname>
                <given-names>VD</given-names>
              </name>
              <name>
                <surname>Gralinski</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Case</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Leist</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Pyrc</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Trantcheva</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bannister</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Babusis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Clarke</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Mackman</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Spahn</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Palmiotti</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ray</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Cihlar</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jordan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Denison</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Baric</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses.</article-title>
            <source>Sci Transl Med</source>
            <year>2017</year>
            <month>Jun</month>
            <day>28</day>
            <volume>9</volume>
            <issue>396</issue>
            <pub-id pub-id-type="pmid">28659436</pub-id>
          </element-citation>
        </ref>
        <ref id="article-122861.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Malin</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Su&#x000e1;rez</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Priesner</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>F&#x000e4;tkenheuer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rybniker</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Remdesivir against COVID-19 and Other Viral Diseases.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>2020</year>
            <month>Dec</month>
            <day>16</day>
            <volume>34</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">33055231</pub-id>
          </element-citation>
        </ref>
        <ref id="article-122861.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amirian</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses.</article-title>
            <source>One Health</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>9</volume>
            <fpage>100128</fpage>
            <pub-id pub-id-type="pmid">32258351</pub-id>
          </element-citation>
        </ref>
        <ref id="article-122861.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beigel</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Tomashek</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Dodd</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Zingman</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Kalil</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Hohmann</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Luetkemeyer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kline</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lopez de Castilla</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Finberg</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Dierberg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tapson</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Patterson</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Paredes</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sweeney</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Short</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Touloumi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lye</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Ohmagari</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Ruiz-Palacios</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Benfield</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>F&#x000e4;tkenheuer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kortepeter</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Atmar</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Creech</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Lundgren</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Babiker</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Pett</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Neaton</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Burgess</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Bonnett</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Makowski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Osinusi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nayak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lane</surname>
                <given-names>HC</given-names>
              </name>
              <collab>ACTT-1 Study Group Members</collab>
            </person-group>
            <article-title>Remdesivir for the Treatment of Covid-19 - Final Report.</article-title>
            <source>N Engl J Med</source>
            <year>2020</year>
            <month>Nov</month>
            <day>05</day>
            <volume>383</volume>
            <issue>19</issue>
            <fpage>1813</fpage>
            <page-range>1813-1826</page-range>
            <pub-id pub-id-type="pmid">32445440</pub-id>
          </element-citation>
        </ref>
        <ref id="article-122861.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vangeel</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chiu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>De Jonghe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Maes</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Slechten</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Raymenants</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Andr&#x000e9;</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Leyssen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Neyts</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jochmans</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.</article-title>
            <source>Antiviral Res</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>198</volume>
            <fpage>105252</fpage>
            <pub-id pub-id-type="pmid">35085683</pub-id>
          </element-citation>
        </ref>
        <ref id="article-122861.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takashita</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Yamayoshi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>van Bakel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sordillo</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Pekosz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fukushi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Maeda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Halfmann</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sakai-Tagawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Imai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hasegawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kawaoka</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants.</article-title>
            <source>N Engl J Med</source>
            <year>2022</year>
            <month>Aug</month>
            <day>04</day>
            <volume>387</volume>
            <issue>5</issue>
            <fpage>468</fpage>
            <page-range>468-470</page-range>
            <pub-id pub-id-type="pmid">35857646</pub-id>
          </element-citation>
        </ref>
        <ref id="article-122861.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siegel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hui</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Doerffler</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Clarke</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Chun</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Neville</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carra</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lew</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Wolfe</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jordan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Soloveva</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Knox</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Perron</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stray</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Barauskas</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rheingold</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Ray</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Bannister</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Strickley</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Swaminathan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Bavari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cihlar</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lo</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Warren</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Mackman</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses.</article-title>
            <source>J Med Chem</source>
            <year>2017</year>
            <month>Mar</month>
            <day>09</day>
            <volume>60</volume>
            <issue>5</issue>
            <fpage>1648</fpage>
            <page-range>1648-1661</page-range>
            <pub-id pub-id-type="pmid">28124907</pub-id>
          </element-citation>
        </ref>
        <ref id="article-122861.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gordon</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Tchesnokov</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>G&#x000f6;tte</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus.</article-title>
            <source>J Biol Chem</source>
            <year>2020</year>
            <month>Apr</month>
            <day>10</day>
            <volume>295</volume>
            <issue>15</issue>
            <fpage>4773</fpage>
            <page-range>4773-4779</page-range>
            <pub-id pub-id-type="pmid">32094225</pub-id>
          </element-citation>
        </ref>
        <ref id="article-122861.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agostini</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Andres</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Sims</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Sheahan</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Case</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Jordan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ray</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Cihlar</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mackman</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Clarke</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Baric</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Denison</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease.</article-title>
            <source>mBio</source>
            <year>2018</year>
            <month>Mar</month>
            <day>06</day>
            <volume>9</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">29511076</pub-id>
          </element-citation>
        </ref>
        <ref id="article-122861.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eastman</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Roth</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Brimacombe</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Simeonov</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Patnaik</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19.</article-title>
            <source>ACS Cent Sci</source>
            <year>2020</year>
            <month>May</month>
            <day>27</day>
            <volume>6</volume>
            <issue>5</issue>
            <fpage>672</fpage>
            <page-range>672-683</page-range>
            <pub-id pub-id-type="pmid">32483554</pub-id>
          </element-citation>
        </ref>
        <ref id="article-122861.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.</article-title>
            <source>Cell Res</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>269</fpage>
            <page-range>269-271</page-range>
            <pub-id pub-id-type="pmid">32020029</pub-id>
          </element-citation>
        </ref>
        <ref id="article-122861.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pruijssers</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Sch&#x000e4;fer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Leist</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Gralinksi</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Dinnon</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Yount</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Agostini</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Chappell</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Gully</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Du Pont</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pitts</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Babusis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Murakami</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Bilello</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Cihlar</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Baric</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Denison</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Sheahan</surname>
                <given-names>TP</given-names>
              </name>
            </person-group>
            <article-title>Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice.</article-title>
            <source>Cell Rep</source>
            <year>2020</year>
            <month>Jul</month>
            <day>21</day>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>107940</fpage>
            <pub-id pub-id-type="pmid">32668216</pub-id>
          </element-citation>
        </ref>
        <ref id="article-122861.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Humeniuk</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mathias</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Osinusi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chng</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ling</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>German</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID-19, in Healthy Subjects.</article-title>
            <source>Clin Transl Sci</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>13</volume>
            <issue>5</issue>
            <fpage>896</fpage>
            <page-range>896-906</page-range>
            <pub-id pub-id-type="pmid">32589775</pub-id>
          </element-citation>
        </ref>
        <ref id="article-122861.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Humeniuk</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mathias</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kirby</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Lutz</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Osinusi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Babusis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ling</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>German</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2021</year>
            <month>May</month>
            <volume>60</volume>
            <issue>5</issue>
            <fpage>569</fpage>
            <page-range>569-583</page-range>
            <pub-id pub-id-type="pmid">33782830</pub-id>
          </element-citation>
        </ref>
        <ref id="article-122861.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>What Do We Know About Remdesivir Drug Interactions?</article-title>
            <source>Clin Transl Sci</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>13</volume>
            <issue>5</issue>
            <fpage>842</fpage>
            <page-range>842-844</page-range>
            <pub-id pub-id-type="pmid">32402130</pub-id>
          </element-citation>
        </ref>
        <ref id="article-122861.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ohmagari</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Diaz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Asperges</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Castagna</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Feldt</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Lescure</surname>
                <given-names>FX</given-names>
              </name>
              <name>
                <surname>Nicastri</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Oda</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Yo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Quiros-Roldan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Studemeister</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Redinski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bernett</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chelliah</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chihara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>D'Arminio Monforte</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ismail</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lapadula</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>L'Her</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Maeno</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Majumder</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Massari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mora-Rillo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mutoh</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Verweij</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zoufaly</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Osinusi</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>DeZure</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chokkalingam</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Elboudwarej</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Telep</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Timbs</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Henne</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Sellers</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Winterbourne</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mera</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gaggar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Myers</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Brainard</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Childs</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Flanigan</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Compassionate Use of Remdesivir for Patients with Severe Covid-19.</article-title>
            <source>N Engl J Med</source>
            <year>2020</year>
            <month>Jun</month>
            <day>11</day>
            <volume>382</volume>
            <issue>24</issue>
            <fpage>2327</fpage>
            <page-range>2327-2336</page-range>
            <pub-id pub-id-type="pmid">32275812</pub-id>
          </element-citation>
        </ref>
        <ref id="article-122861.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mulangu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dodd</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Davey</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Tshiani Mbaya</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Proschan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mukadi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lusakibanza Manzo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nzolo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tshomba Oloma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ibanda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Coulibaly</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Grais</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Diaz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lane</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Muyembe-Tamfum</surname>
                <given-names>JJ</given-names>
              </name>
              <collab>PALM Writing Group</collab>
              <name>
                <surname>Sivahera</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Camara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kojan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dighero-Kemp</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mukumbayi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mbala-Kingebeni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ahuka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Albert</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bonnett</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Crozier</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Duvenhage</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Proffitt</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Teitelbaum</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moench</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Aboulhab</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Barrett</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cahill</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cone</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Eckes</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hensley</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Herpin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Higgs</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ledgerwood</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pierson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Smolskis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sow</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tierney</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sivapalasingam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Holman</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Gettinger</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Vall&#x000e9;e</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nordwall</surname>
                <given-names>J</given-names>
              </name>
              <collab>PALM Consortium Study Team</collab>
            </person-group>
            <article-title>A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.</article-title>
            <source>N Engl J Med</source>
            <year>2019</year>
            <month>Dec</month>
            <day>12</day>
            <volume>381</volume>
            <issue>24</issue>
            <fpage>2293</fpage>
            <page-range>2293-2303</page-range>
            <pub-id pub-id-type="pmid">31774950</pub-id>
          </element-citation>
        </ref>
        <ref id="article-122861.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ruan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mei</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Gu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Jaki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hayden</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Horby</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.</article-title>
            <source>Lancet</source>
            <year>2020</year>
            <month>May</month>
            <day>16</day>
            <volume>395</volume>
            <issue>10236</issue>
            <fpage>1569</fpage>
            <page-range>1569-1578</page-range>
            <pub-id pub-id-type="pmid">32423584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-122861.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lescure</surname>
                <given-names>FX</given-names>
              </name>
              <name>
                <surname>Bouadma</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Parisey</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wicky</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Behillil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gaymard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bouscambert-Duchamp</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Donati</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Le Hingrat</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Enouf</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Houhou-Fidouh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Valette</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mailles</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lucet</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Mentre</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Duval</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Descamps</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Malvy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Timsit</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Lina</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>van-der-Werf</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yazdanpanah</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Clinical and virological data of the first cases of COVID-19 in Europe: a case series.</article-title>
            <source>Lancet Infect Dis</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>20</volume>
            <issue>6</issue>
            <fpage>697</fpage>
            <page-range>697-706</page-range>
            <pub-id pub-id-type="pmid">32224310</pub-id>
          </element-citation>
        </ref>
        <ref id="article-122861.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <collab>COVID-19 Investigation Team</collab>
            <article-title>Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States.</article-title>
            <source>Nat Med</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>26</volume>
            <issue>6</issue>
            <fpage>861</fpage>
            <page-range>861-868</page-range>
            <pub-id pub-id-type="pmid">32327757</pub-id>
          </element-citation>
        </ref>
        <ref id="article-122861.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spinner</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Gottlieb</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Criner</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Arribas L&#x000f3;pez</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Cattelan</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Soriano Viladomiu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ogbuagu</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Malhotra</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mullane</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Castagna</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chai</surname>
                <given-names>LYA</given-names>
              </name>
              <name>
                <surname>Roestenberg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tsang</surname>
                <given-names>OTY</given-names>
              </name>
              <name>
                <surname>Bernasconi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Le Turnier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>SenGupta</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hyland</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Osinusi</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Blair</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gaggar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brainard</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>McPhail</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Bhagani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Sanyal</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Huhn</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Marty</surname>
                <given-names>FM</given-names>
              </name>
              <collab>GS-US-540-5774 Investigators</collab>
            </person-group>
            <article-title>Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.</article-title>
            <source>JAMA</source>
            <year>2020</year>
            <month>Sep</month>
            <day>15</day>
            <volume>324</volume>
            <issue>11</issue>
            <fpage>1048</fpage>
            <page-range>1048-1057</page-range>
            <pub-id pub-id-type="pmid">32821939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-122861.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldman</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Lye</surname>
                <given-names>DCB</given-names>
              </name>
              <name>
                <surname>Hui</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Marks</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Bruno</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Montejano</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Spinner</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Galli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Nahass</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>SenGupta</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hyland</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Osinusi</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Blair</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Gaggar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brainard</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Towner</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Mu&#x000f1;oz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mullane</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Marty</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Tashima</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Diaz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Subramanian</surname>
                <given-names>A</given-names>
              </name>
              <collab>GS-US-540-5773 Investigators</collab>
            </person-group>
            <article-title>Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.</article-title>
            <source>N Engl J Med</source>
            <year>2020</year>
            <month>Nov</month>
            <day>05</day>
            <volume>383</volume>
            <issue>19</issue>
            <fpage>1827</fpage>
            <page-range>1827-1837</page-range>
            <pub-id pub-id-type="pmid">32459919</pub-id>
          </element-citation>
        </ref>
        <ref id="article-122861.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burwick</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Yawetz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stephenson</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Collier</surname>
                <given-names>AY</given-names>
              </name>
              <name>
                <surname>Sen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Blackburn</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Kojic</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Hirshberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Suarez</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Sobieszczyk</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Marks</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Mazur</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Big</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Manuel</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Morlin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Naqvi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goldfarb</surname>
                <given-names>IT</given-names>
              </name>
              <name>
                <surname>DeZure</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Telep</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hahambis</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hindman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chokkalingam</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Osinusi</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Brainard</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Varughese</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Kovalenko</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Sims</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Swamy</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sheffield</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Zash</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Short</surname>
                <given-names>WR</given-names>
              </name>
            </person-group>
            <article-title>Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019.</article-title>
            <source>Clin Infect Dis</source>
            <year>2021</year>
            <month>Dec</month>
            <day>06</day>
            <volume>73</volume>
            <issue>11</issue>
            <fpage>e3996</fpage>
            <page-range>e3996-e4004</page-range>
            <pub-id pub-id-type="pmid">33031500</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
